Pharm-Olam Strengthens Leadership Team with New CFO
Pharm-Olam LLC announces the promotion of Natalie Gassen to the position of Chief Financial Officer. DECEMBER 20, 2015 Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is proud to announce the promotion of Natalie Gassen to the position of Chief Financial Officer. Natalie brings to Pharm-Olam […]
Pharm-Olam International Expands to Larger Facility in Poland
Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization (CRO) to biopharmaceutical and device industries, is proud to announce the relocation of its Polish location to a larger office to accommodate for its growing staff. OCTOBER 13, 2015 Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization (CRO) to biopharmaceutical and device industries, […]
Pharm-Olam International Opens a New Office in Paris, France; Continues Global Expansion
HOUSTON, TEXAS – Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization (CRO) to biopharmaceutical and device industries, is proud to announce the opening of a new, fully-staffed office in Paris, France. JUNE 11, 2015 HOUSTON, TEXAS – Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization (CRO) to biopharmaceutical and device industries, […]
Pharm-Olam’s Case Study on Automated Sample Retention for BA/BE
This case study reviews Pharm-Olam’s Automated Sample Retention Solution that was used in a recent study. MARCH 12, 2015 Bioavailability and Bioequivalence (BA/BE) studies require samples of investigational product retained. Typically, this is performed manually and overseen by clinical monitors during site initiation. This manual approach is feasible for limited sites, but larger site numbers […]
Pharm-Olam: Phase III Pulmonary Arterial Hypertension study completed
A case study by Pharm-Olam for a Phase III study designed to address the efficacy and safety for a compound for pulmonary arterial hypertension patients. FEBRUARY 12, 2015 Pharm-Olam was selected to provide development services for a Phase III study, which was designed to address the efficacy and safety for a compound for pulmonary arterial […]
Pharm-Olam releases a corporate overview video
To learn more about the benefits that Pharm-Olam offers click here to view the video. JANUARY 12, 2015 To learn more about the benefits that Pharm-Olam offers click here to view the video.